| Product NDC: | 10019-106 |
| Proprietary Name: | Lorazepam |
| Non Proprietary Name: | Lorazepam |
| Active Ingredient(s): | 4 mg/mL & nbsp; Lorazepam |
| Administration Route(s): | INTRAMUSCULAR; INTRAVENOUS |
| Dosage Form(s): | INJECTION, SOLUTION |
| Coding System: | National Drug Codes(NDC) |
| Product NDC: | 10019-106 |
| Labeler Name: | BAXTER HEALTHCARE CORPORATION |
| Product Type: | HUMAN PRESCRIPTION DRUG |
| FDA Application Number: | NDA018140 |
| Marketing Category: | NDA |
| Start Marketing Date: | 20050923 |
| Package NDC: | 10019-106-02 |
| Package Description: | 10 VIAL, MULTI-DOSE in 1 PACKAGE (10019-106-02) > 10 mL in 1 VIAL, MULTI-DOSE (10019-106-71) |
| NDC Code | 10019-106-02 |
| Proprietary Name | Lorazepam |
| Package Description | 10 VIAL, MULTI-DOSE in 1 PACKAGE (10019-106-02) > 10 mL in 1 VIAL, MULTI-DOSE (10019-106-71) |
| Product NDC | 10019-106 |
| Product Type Name | HUMAN PRESCRIPTION DRUG |
| Non Proprietary Name | Lorazepam |
| Dosage Form Name | INJECTION, SOLUTION |
| Route Name | INTRAMUSCULAR; INTRAVENOUS |
| Start Marketing Date | 20050923 |
| Marketing Category Name | NDA |
| Labeler Name | BAXTER HEALTHCARE CORPORATION |
| Substance Name | LORAZEPAM |
| Strength Number | 4 |
| Strength Unit | mg/mL |
| Pharmaceutical Classes | Benzodiazepine [EPC],Benzodiazepines [Chemical/Ingredient] |